Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garadacimab (CSL312) in Hereditary Angioedema (Phase 2)
NCT03712228Phase 2Completed
- Sponsor
- CSL Limited
- Start
- Oct 2018
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of garadacimab in hereditary angioedema (HAE) (5 arms), sponsored by CSL Limited. Primary endpoint: Mean Time Normalized Number of HAE Attacks Per Month at 13 weeks. Started Oct 2018; status: completed.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT03712228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712228.